Background Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high
response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had …

Diagnosis and management of immune thrombocytopenic purpura (ITP) remain largely
dependent on clinical expertise and observations more than on evidence derived from clinical …

Information was obtained by questionnaire about 215 nonhemophilic patients who developed
inhibitors against factor VIII (antihemophilic factor). The majority of the patients were over …

Background A high plasma level of factor VIII is a risk factor for venous thromboembolism.
We evaluated the risk of a recurrence of thrombosis after an initial episode of spontaneous …

In the murine system, a number of cytokines (including interleukin-3 [IL-3], IL-4, and stem cell
factor [SCF]) promote the growth of mast cells (MCs). However, so far little is known about …

Autoimmune hemolytic anemia is a heterogeneous disease with respect to the type of the
antibody involved and the absence or presence of an underlying condition. Treatment …

OBJECTIVE: Because of its potent immunosuppressive properties in vitro as well as in vivo,
we studied the effect of 1,25-dihydroxyvitamin D 3 (calcitriol) on differentiation, maturation, …

The safety and efficacy of filgrastim as an adjunct to acute myeloid leukemia (AML) induction
and consolidation therapy was assessed in this prospective double-blind, randomized, …

There is strong evidence that the incidence of venous thromboembolism (VTE) is increased
during pregnancy. However, it is unknown whether and to which extent pregnancy …

To prospectively assess the role of MDR1 gene expression in patients with de novo acute
myeloid leukemia (AML), levels of MDR1 RNA in blast cells were determined at diagnosis and …